|
Figure 1. Characterization of insulin3 in Xenopus. (a) Stage PCR for insulin3. Stages of samples are indicated (top). (b) Whole-mount in situ hybridization of insulin3 transcripts. Stages of samples are indicated (right). Viewpoints are indicated (top). The line indicates the position of the cross-section. (c) mRNAs were injected into the animal pole of two-cell-stage X. laevis embryos. Embryos were harvested at stage 30. Amounts of mRNA injected per embryos were: insulin1 (2âng), IGF1 (300âpg) and insulin3 (300âpg). Expanded cement gland was induced by injection of insulin3 and IGF1, but not by injection of insulin1. (d) Animal cap assay. One ng of IGF1 and insulin3 mRNAs were injected into the animal pole of both blastomeres at the two-cell stage in X. laevis embryos. Animal caps were dissected at stage 9 and harvested at stage 11. IGF1 and Insulin3 induce otx2 and inhibit without induction of BMP antagonists. WE: whole embryo. RT-: reverse transcriptase minus reaction. Full-length gels are presented in Supplementary figure S7.
|
|
Figure 2: Insulin3-deficient embryos showed anterior defects in both X. laevis and X. tropicalis. A translation-inhibiting MO was designed for X. laevis insulin3 and a splice-inhibiting MO for X. tropicalis insulin3. Forty ng and 12âng of MOs were injected into the marginal zone of both blastomeres at the two-cell stage in (a) X. laevis and (b) X. tropicalis embryos, respectively. (a) Insulin3 MO induced anterior defects in X. laevis embryos. Insulin3 MO specifically inhibited the translation of 5â²UTR-insulin3-HA, which has the targeted sequence of MO, but not mis-insulin3-HA, which has 7 mismatches in the targeted sequences. (b) Xt. insulin3 S MO induced anterior defects in X. tropicalis embryos. Xt. insulin3 S MO inhibited normal splicing of insulin3 mRNA. Full-length blots and gels are presented in Supplementary figure S7.
|
|
Figure 3: Insulin3 is essential for anterior neural marker gene expression. (a) Anterior views of stage 15 embryos. Expressions of anterior neural marker genes, cg1, bf1, rx1, otx2, sox2, and sox3, were increased by injection of insulin3 mRNA. In contrast, insulin3 MO injection decreased the expression of these genes. (b) Dorsal views of stage 10.5 embryos. Dorsal mesodermal maker genes, gsc and chd, were not affected by injection of insulin3 mRNA or insulin3 MO.
|
|
Figure 4: Insulin3 also inhibit BMP signaling like a Wnt signalling inhibitor, dkk1. mRNAs were injected into the animal pole of both blastomeres at the two-cell stage in X. laevis embryos. (a) Amounts of mRNA injected per embryos were: chd (25âpg), insulin3 (250âpg), and dkk1 (250âpg). Over-expression of insulin3 shows similar anteriorised phenotype to a Wnt signalling inhibitor, dkk1, not dorsalized phenotype like a BMP signaling inhibitor, chordin. (b,c) qRT-PCR analyses of animal caps (b) Amounts of mRNA injected per embryos were: wnt8 (10âpg) and insulin3 (500âpg). Animal caps were dissected at stage 9 and harvested at stage 10.5. Insulin3 inhibits the expression of Wnt signal target genes, siamois and nodal3. WE: whole embryo. RT-: reverse transcriptase minus reaction. (c) Amounts of mRNA injected per embryos were: bmp4, chordin, insulin3 and dkk1 (1âng). Insulin3 down-regulates expression of BMP target genes, msx1, vent1, and bra, like dkk1 at St. 10.5 animal caps. Expression level were normalized to odc, and scaled to the average value of the wnt8 or bmp4 injected samples; the fold difference between the control and each sample is shown. The data represent meanâ±âs.e.m (nâ=â3). *Pâ<0.05; **Pâ<â0.01; ***Pâ<â0.001; (t-test, two tailed).
|
|
Figure 5: Rescue experiments of insulin3 over-expressed or knockdown phenotypes by modulation of Wnt signalling. (aâd) Rescue of insulin3 over-expressed phenotype by treatment of Wnt signal activator, LiCl. (a) Uninjected control embryos. (b,c) Microinjection of 500âpg of insulin3 mRNA at the two-cell stage induces giant cement gland (b). This phenotype is inhibited by treatment of 0.3M LiCl at the gastrulae stage for 5âmin. (c). (d) LiCl treatment can rescue enlarged cement gland induced by insulin3 over-expression. Phenotypic index: Small, small-sized cement gland and head structure. Large, enlarged cement gland. Phenotypes were counted at St. 25. (eâh) Rescue of insulin3 MO phenotype by mouse dkk1 protein. (e) Uninjected control embryos. (f,g) Microinjection of 30âng insulin3 MO at the two-cell stage induces anterior defects with small eyes (f). This phenotype is rescued by the injection of mouse dkk1 protein (1âng) into blastocoel at St. 9 (g). (h) Dkk1 protein injection into the blastocoel can rescue small-sized eye phenotypes in insulin3 morphant. Phenotypic index: small, small-sized eye. Large, enlarged eye.
|
|
Figure 6: Insulin3 inhibits Wnt signalling but cannot activate the IGF1 receptor. mRNAs were injected into the animal pole of both blastomeres at the two-cell stage in X. laevis embryos. (a) One ng of insulin3, IGF1, or IGF1R mRNA was injected per embryo. Embryos were harvested at stage 11 for western blot analysis. (b) One ng of Myc-tagged extracellular domain of IGF1 receptor (IGF1Rex-Myc), IGF1-HA, insulin3-HA, or insulin1-HA mRNA was injected per embryo. Embryos were harvested at stage 10.5 for co-immunoprecipitation assay. (c,d,e) Amounts of mRNA injected per embryos were: (c) FGF4 (10âpg), (d) insulin3 (100âpg), and (e) IGF1 (100âpg). Animal caps were dissected at stage 9 and treated with chemical MEK inhibitors, PD98059 (100âμM) and U0126 (100âμM) until sibling embryos reached stage 10.5. (c) Bra expression induced by FGF4 was inhibited, but otx2 expression induced by (d) insulin3 or (e) IGF1 was not. Full-length blots and gels are presented in Supplementary figure S8.
|
|
Figure 7: Insulin3 is predominantly localised in the endoplasmic reticulum. (a) mRNAs were injected into the animal pole of both blastomeres at the two-cell stage in X. laevis embryos. Amounts of mRNA injected per embryos were: insulin3-HA (500âpg), CAAX-GFP (250âpg), and sec61β-GFP (250âpg). CAAX-GFP and Sec61β-GFP are localised at the plasma membrane and endoplasmic reticulum, respectively. Embryos were fixed at stage 11. Immunohistochemistry was performed using antibodies against HA-tag and GFP. Animal cap regions were used for analysis. Insulin3-HA was predominantly co-localised with Sec61β-GFP at the endoplasmic reticulum. (b) One ng of mRNAs was injected into the animal pole of both blastomeres at the two-cell stage in X. laevis embryos. Blastocoel fluids were collected at stage 10.5. One μL of the blastocoel fluid was used for western blotting. The lysate was equivalent to one embryo. Insulin3-HA was secreted into the blastocoel at lower efficiency than other insulin family members. Full-length blots are presented in Supplementary figure S9. (c) mRNAs were injected into the animal pole of one blastomere at the two-cell stage in X. laevis embryos. Amounts of mRNA injected per embryos were: b-gal (250âpg), dkk1 (500âpg), and insulin3-HA (500âpg). Anterior view of stage 20 embryos. Red-gal staining indicated the injected-side. The effect of insulin3-HA was in a cell-autonomous manner, unlike dkk1.
|
|
Figure 8: Insulin3 reduced the total amount of extra-cellular Wnt8 and membrane-localised Lrp6, but not Frizzled8. (a) Anti-Myc immunoprecipitation (IP). mRNAs was injected into the animal pole of both blastomeres at the two-cell stage in X. laevis embryos. One ng of insulin3-HA, wnt8-Myc, frizzled8-Myc, or lrp6-Myc mRNA was injected per embryo. Embryos were harvested at stage 10.5 for co-immunoprecipitation assay. (b,c,d) mRNAs were injected into the animal pole of both blastomeres at the two-cell stage in X. laevis embryos. Amounts of mRNA injected per embryos were: wnt8-Myc (500âpg), lrp6-Myc (500âpg), frizzled8-Myc (500âpg), sec61β-GFP (1âng), and insulin3-HA (1âng). Sec61β-GFP was used as an ER-localised control instead of cytoplasmic GFP because insulin3-HA was localised in ER (Fig. 7). (b) Confocal micrographs of ectodermal explants. Embryos were fixed and immunostained with anti-Myc antibody (red) for Wnt8-Myc, Lrp6-Myc, and Frizzled8-Myc at stage 11. Ectodermal explants were dissected after staining and mounted with DAPI. Insulin3 decreased cell-surface levels of Wnt8-Myc, Lrp6-Myc, but not Frizzled8-Myc. (c) Western blot analysis of embryo lysates. Insulin3 decreased the total amount of Wnt8-Myc. Insulin3 also reduced the mature form of Lrp6-Myc (upper band) which localised at the plasma membrane. Frizzled8-Myc had no effects. (d) Western blot analysis of embryo lysates treated with PNGaseF or EndoH as indicated. Insulin3 reduced EndoH-resistant mature form of Lrp6. dg, deglycosylated form; im, EndoH-sensitive immature form; ma, EndoH-resistant mature form. (e) Quantification of the Western blotting in (c) and (d). The protein bands in the blots from three independent experiments were quantified by using ImageJ for densitometry. The amount of protein in control (+Sec61β) was designated as 100%. Error bar indicate the SEM of these experiments. The data are presented as meanâ±âs.e.m. NS (not significant, Pâ>â0.05), *Pâ<â0.05; **Pâ<â0.01; ***Pâ<â0.001; (t-test, two tailed). Full-length blots are presented in Supplementary figure S9.
|
|
Figure S1. Synteny analysis of insulin/IGF locus.
Using Metazome [(http://www.metazome.net/) ©2006-2014 University of California Regents], the
flanking upstream and downstream genes of the Insulin and IGF orthologs were compared between
H. sapiens, M. musculus, and X. tropicalis. The gene and the transcriptional direction are indicated
by the colour and direction of the box, respectively. The synteny around IGF1 locus is conserved
between H. sapiens and X. tropicalis. The synteny around IGF2 locus is conserved among these
three species. IGF2 and insulin are located nearby. The locus of the insulin3 and IGF3 is not
conserved among other species.
|
|
Figure S2. Protein features of Insulin3.
(a) Phylogenetic analysis using protein sequences of the Insulin family. The phylogenetic tree was
calculated by MacVector 11.1.0 software. Human Insulin (AAA59172), human IGF1 (CAA01955),
human IGF2 (NP_000603), human Relaxin1 (CAA00599), human Relaxin2 (AAI26416), human
Relaxin3 (AAI40936), human LNSL4 (AAH26254), human INSL5 (AAQ89389), human INSL6
(AAD39003), X. laevis Insulin1 (NP_001079351), X. laevis Insulin2 (NP_001079350), X. laevis
Insulin3 (Translation of Contig029272 released from XDB3), X. laevis IGF1 (NP_001156865), X.
laevis IGF2 (AAL11445), and X. laevis IGF3 (NP_001082137) were tested. Silkworm Bombyxin
(BAA00246) was used as the outgroup. (b) Amino acid sequence alignment indicates that Insulin3
has 6 cysteine residues conserved among the Insulin family, and no proteolytic cleavage sites that are
required to release C-peptide. The cysteine residues boxed with the same colour form intramolecular
S-S bands. (c) Schematic illustration of Insulin, IGF1, IGF2, and Insulin3 protein processing. Insulin
and IGF molecules are synthesized as inactive prepropeptides that are converted to a mature active
form by endoproteolysis, thereby releasing C-peptide and E-peptide, respectively. Insulin3-HA has an
HA tag at the C-terminus and shows the same activity as the native form (data not shown). Insulin3-
HA mRNA (1 ng) was injected into the animal pole of two-cell-stage X. laevis embryos. Embryos
were harvested at stage 10.5. Western blot analysis showed that Insulin3-HA is not proteolytically
processed to release C-peptide.
|
|
Figure S3. Five-mismatch MOs showed no significant effects.
(a, b) Forty ng of MOs were injected into the marginal zone of both blastomeres at the two-cell stage in X.
laevis embryos. (a) Insulin3 5mis MO showed no effect on X. laevis development, unlike insulin3 MO. (b)
Dorsal views of stage 10.5 embryos. Dorsal mesodermal maker genes, gsc and chd, were not affected by
injection of insulin3 5mis MO or insulin3 MO. Anterior views of stage 15 embryos. Expressions of anterior
neural marker genes, cg1, bf1, rx1, otx2, sox2, and sox3, were not affected by injection of insulin3 5mis
MO, unlike insulin3 MO. (c) Twelve ng of MOs were injected into the marginal zone of both blastomeres at
the two-cell stage in X. tropicalis embryos. Xt. insulin3 S 5mis MO showed no effects on X. tropicalis
development, unlike Xt. insulin3 S MO. Numbers of embryos with the shown phenotype are indicated in
panels.
|
|
Figure S4. Insulin3 and IGF1R did not show synergistic effects for anteriorisation.
(a) mRNAs were injected into the animal pole of both blastomeres at the two-cell stage in X. laevis
embryos. Embryos were fixed at stage 30. Amounts of mRNA injected per embryos were: IGF1
(500 pg), insulin3 (500 pg), IGF1R (1 ng), and insulin1 (2 ng). Injected RNA is indicated in each
panel. Co-injection of IGF1R and IGF1 or insulin mRNAs showed a posteriorising effect and
induced protrusions (arrowheads). Numbers of embryos with the shown phenotype are IGF1
(29/30), IGF1 + IGF1R (21/30), insulin3 (30/30), insulin3 + IGF1R (28/30), insulin (30/30), insulin
+ IGF1R (11/30). (b) Western blot analysis of animal caps. mRNAs were injected into the animal
pole of both blastomeres at the two-cell stage in X. laevis embryos. Amounts of mRNA injected per
embryos were: IGF1 (1 ng), insulin3 (1 ng), and DN-IGF1R (1 ng). Animal caps were dissected at
stage 9 and were cultured in Steinberg's solution (SS) until stage 11.
|
|
Figure S5. IGF1 protein treatment did not show any effect on anterior development.
(a) Recombinant proteins were injected into the blastocoel. Amounts of protein injected per embryos
were: BSA, IGF1, Lefty1, Dkk1 (2 μg/20 nL, respectively), and bFGF (1 μg/20 nL). The ratio of
embryos with the shown phenotype were 100% (nâ¥30). (b) Oocytes at stage VI were treated with
recombinant human IGF1 in OR2 medium (0.1% BSA) for 3 h. Recombinant human IGF1 can
activate downstream targets of IGF1 receptor, Akt and Erk in oocytes.
|
|
Figure S6. IGF1 has similar activity to Insulin3.
Western blot analysis of embryo lysates. mRNAs was injected into the animal pole of both
blastomeres at the two-cell stage in X. laevis embryos. Embryos were harvested at stage 11 for
western blot analysis. Amounts of mRNA injected per embryos were: wnt8-Myc (100 pg), wnt3a-Myc
(100 pg), lrp6-Myc (500 pg), sec61β-GFP (1 ng), insulin3-HA (1 ng) and IGF1-HA (1 ng). (a, b)
Insulin3-HA decreased the total amount of Wnt8-Myc (a) and Wnt3a-Myc (b). IGF1-HA also
decreased Wnt3a-Myc (b) but not Wnt8-Myc (a). (c) Insulin3-HA decreased levels of the mature form
of Lrp6-Myc that localized to the plasma membrane. IGF1-HA had a slight effect on mature form of
Lrp6-Myc and increased the non-glycosylated form of Lrp6. Numbers indicate the molecular weight
of proteins (kDa).
|
|
Figure S7. Full-length blots and gels in Figure 1 and 2.
Dashed boxes indicate the portion of the blot and gel included in the figures.
|
|
Figure S8. Full-length blots and gels in Figure 6.
Dashed boxes indicate the portion of the blot and gel included in the figures.
|
|
Figure S9. Full-length blots in Figure 7 and 8.
Dashed boxes indicate the portion of the blot included in the figures. The membrane used to generate
Figure 8a, 8c, and 8d were cut into two or three sections and developed with different antibodies.
The black line indicates the position of the cut.
|